Physician profile
Jose Matus
NPI 1841298270
$780.67
in general payments reported to CMS, 2019-2025
20 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $48.82 · 2021: $211 · 2022: $84.76 · 2023: $70.34 · 2024: $38.80 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82.62 | 2021-2025 | |
| Boston Scientific Corporation | $79.48 | 2021 | |
| Amgen INC. | $73.70 | 2025 | Uplizna |
| Sk Life Science, INC. | $64.94 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $52.11 | 2019-2022 | |
| Mdd US Operations, LLC | $51.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $49.77 | 2019-2021 | |
| Abbott Laboratories | $45.04 | 2024-2025 | Proclaim, Infinity |
| Alexion Pharmaceuticals, INC. | $43.83 | 2019-2023 | Ultomiris |
| Ucb, INC. | $40.82 | 2021-2023 | Fintepla |
| Eisai INC. | $30.92 | 2025 | |
| Neurocrine Biosciences, INC. | $26.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.96 | 2021 | |
| Axsome Therapeutics, INC. | $19.91 | 2025 | Symbravo |
| Arbor Pharmaceuticals, INC. | $17.84 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.49 | 2024 | Enspryng, Ocrevus |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.67 | 2022 | |
| Celgene Corporation | $15.21 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.94 | 2021 | |
| Livanova USA, INC. | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Matus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.